Volume: 46 Issue: 1
Year: 2026, Page: 62-66, Doi: https://doi.org/10.51248/v46i1.225
Received: Dec. 11, 2025 Accepted: March 7, 2026 Published: March 10, 2026
Background: Breast carcinoma remains a serious global health concern, with over 2.3 million women diagnosed annually and significant mortality rates persisting despite improvements in screening and treatment protocols. Aim: This is an observational, case control, hospital-based study which was carried out to find the role of inflammatory markers in patients with breast carcinoma and their correlation with tumour markers. Metrials & Methods: The study population consists of (3) three distinct study groups, Group A: patients diagnosed with breast carcinoma (n=70), Group B: healthy controls (n=70) and Group C: patients with benign breast disease (n=70). Patients suffering from any tumor of breast identified for the first time were included in this study population. Recurrent cases were excluded from the study. Serum level of CRP and IL-6 were measured as inflammatory marker whereas CEA and CA 15 - 3 were measured as tumour markers in this study population. Results: There was significant elevation of inflammatory markers in patients with breast carcinoma when compared to healthy control. The inflammatory markers were found to be positively correlated with patients with breast carcinoma but this correlation was not significant. Conclution: Early detection of elevated inflammatory markers could serve as a predictive tool for breast cancer prognosis. Integrating CRP and IL-6 screening in routine diagnostics may help identify high-risk patients earlier.
Keywords: CRP, IL 6, Breast Carcinoma, Early Diagnosis, correlation, Tumour marker
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249
2. Mehrotra R, Yadav K. Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol. 2022 Mar 24;13(3):209- 218
3. Shao Y, Sun X, He Y, Liu C, Liu H. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLoS One. 2015 Jul 24;10(7): e0133830.
4. Pierce BL, Ballard-Barbash R, Bernstein L, et al., Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27: 3437-4
5. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec 19- 26;420(6917):860-7.
6. Tang S, Zhou F, Sun Y, Wei L, Zhu S, Yang R, Huang Y, Yang J. CEA in breast ductal secretions as a promising biomarker for the diagnosis of breast cancer: a systematic review and meta-analysis. Breast Cancer. 2016;23(6):813-819.
7. Hashim ZM. The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status. Int J Immunopathol Pharmacol. 2014;27(1):45-51.
8. Fejzić H, Mujagić S, Azabagić S, Burina M. Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad. 2015;44(1):39-46.
9. Abdollahi A, Ali-Bakhshi A, Farahani Z. Concentration Study of High Sensitive C - reactive Protein and some Serum Trace Elements in Patients with Benign and Malignant Breast Tumor. Int J Hematol Oncol Stem Cell Res. 2015;9(4):180-4.
10. Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, Lu J, Sun X. C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. Sci Rep. 2015; 5:10508.
11. Sanguinetti, A., Santini, D., Bonafè, M. et al. Interleukin-6 and pro inflammatory status in the breast tumor microenvironment. World J Surg Onc 2015; 13:.129
12. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357539-545.
13. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553-11572.
14. Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M, JadidiNiaragh F. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother. 2018; 108:1415-1424
Soma Gupta, Sukanya Mukherjee, Sukla Nath. Role of Inflammatory markers in patients with breast carcinoma and their correlation with Tumor markers. Biomedicine: 2026, 46(1): 62-66